Clinical Trial Update: Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase II trial assessing AUY922 versus comparators in advanced gastric cancer and gastro-esophageal junction cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastro-esophageal Junction Cancer

Drugs mentioned

• AUY922 (luminespib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Gastric Cancer, Gastro-esophageal Junction Cancer | Phase 2 | Status: COMPLETED